Clementia Pharmaceuticals Inc. (CMTA) Given $27.00 Average Target Price by Brokerages

Shares of Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) have received a consensus broker rating score of 1.13 (Strong Buy) from the four brokers that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy recommendation and three have assigned a strong buy recommendation to the company. Clementia Pharmaceuticals’ rating score has improved by 3.4% in the last 90 days as a result of a number of analysts’ ratings changes.

Brokers have set a one year consensus price target of $27.00 for the company, according to Zacks. Zacks has also assigned Clementia Pharmaceuticals an industry rank of 111 out of 265 based on the ratings given to related companies.

A number of equities analysts recently weighed in on the stock. Wedbush restated an “outperform” rating and issued a $26.00 price objective on shares of Clementia Pharmaceuticals in a report on Tuesday, November 14th. Leerink Swann assumed coverage on shares of Clementia Pharmaceuticals in a research note on Monday, August 28th. They set an “outperform” rating and a $23.00 target price for the company. BTIG Research assumed coverage on shares of Clementia Pharmaceuticals in a research note on Thursday, August 31st. They set a “buy” rating and a $32.00 target price for the company. Finally, Morgan Stanley assumed coverage on shares of Clementia Pharmaceuticals in a research note on Monday, August 28th. They set an “overweight” rating and a $27.00 target price for the company.

Shares of Clementia Pharmaceuticals (NASDAQ:CMTA) traded up $0.35 during midday trading on Tuesday, reaching $16.85. 20,282 shares of the company were exchanged, compared to its average volume of 110,397. Clementia Pharmaceuticals has a 52 week low of $15.05 and a 52 week high of $18.95.

Institutional investors and hedge funds have recently made changes to their positions in the business. Birchview Capital LP purchased a new stake in Clementia Pharmaceuticals during the 3rd quarter valued at $372,000. Victory Capital Management Inc. bought a new stake in shares of Clementia Pharmaceuticals during the 3rd quarter valued at $520,000. Susquehanna International Group LLP bought a new stake in shares of Clementia Pharmaceuticals during the 3rd quarter valued at $729,000. Neuberger Berman Group LLC bought a new stake in shares of Clementia Pharmaceuticals during the 3rd quarter valued at $1,689,000. Finally, Point72 Asset Management L.P. bought a new stake in shares of Clementia Pharmaceuticals during the 3rd quarter valued at $506,000. Institutional investors and hedge funds own 15.02% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.com-unik.info/2017/11/21/clementia-pharmaceuticals-inc-cmta-given-27-00-average-target-price-by-brokerages.html.

Clementia Pharmaceuticals Company Profile

Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models.

Get a free copy of the Zacks research report on Clementia Pharmaceuticals (CMTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about Clementia Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Clementia Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit